Preoperative TDM1 in Germany
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. (ADAPT; T-DM1)
http://clinicaltrials.gov/show/NCT01745965 The Europeans aren't dragging their feet with TDM1 and early stage breast cancer. Since this is neoadjuvant I am hoping to seeing the data much sooner than in a typical study. Interesting opportunities. |
All times are GMT -7. The time now is 12:27 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021